wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q51732438-E7DA3D26-0301-487D-91A5-85687CBBF1E7
Q51732438-E7DA3D26-0301-487D-91A5-85687CBBF1E7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51732438-E7DA3D26-0301-487D-91A5-85687CBBF1E7
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
P2860
Q51732438-E7DA3D26-0301-487D-91A5-85687CBBF1E7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51732438-E7DA3D26-0301-487D-91A5-85687CBBF1E7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
910f54123037e1d4cb48462066a32498842427cc
P2860
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.